Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a positive outlook for its stock performance relative to the market [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, reflecting a year-on-year growth of 21.8%, and a net profit attributable to shareholders of 237 million yuan, up 33.9% [5][8]. - In Q4 2025, the company achieved a revenue of 262 million yuan, a 21.5% increase year-on-year, and a net profit of 78 million yuan, which is a 26.4% increase [5][8]. - The company is expanding its generic drug product line while simultaneously advancing its new drug development, with a focus on cost reduction and efficiency improvements [5][8]. Financial Data and Profit Forecast - The company’s total revenue is projected to be 1.171 billion yuan in 2026, with a slight decrease to 1.110 billion yuan in 2027 [7]. - The net profit forecast for 2025 is 237 million yuan, followed by 174 million yuan in 2026 and 140 million yuan in 2027, indicating a decline in profitability in the following years [7][9]. - The company’s gross margin is expected to decrease from 83.4% in 2025 to 71.6% in 2027, reflecting potential pricing pressures from market competition [7]. Generic Drug Business - The sales of core products such as "复瑞彤" and "波开清" are steadily increasing, driving growth for the company [8]. - The company is proactively expanding its portfolio of generic drugs, with eight new drug registration approvals obtained in 2025 [8]. Innovative Drug Business - The company is advancing its pipeline of innovative drugs, with the DYX116 project progressing as expected, having completed Phase I clinical trials [8]. - The market for GLP-1 drugs in China is projected to reach 609 billion yuan by 2030, indicating significant growth potential for the company’s innovative drug offerings [8].

Core Viewpoint - Shengnuo Biotech is a leading domestic peptide drug research and production enterprise, with a comprehensive R&D pipeline and full industry chain platform for peptide APIs and formulations [1] Group 1: Business Overview - Shengnuo Biotech was established on July 23, 2001, and listed on the Shanghai Stock Exchange on June 3, 2021, with its registered and office address in Chengdu, Sichuan Province [1] - The main business includes peptide innovative drug CDMO services, self-developed and sold peptide APIs and formulations, customized production services for peptide products, and technology transfer services for peptide drug production [1] Group 2: Financial Performance - In Q3 2025, Shengnuo Biotech reported revenue of 520 million yuan, ranking 79th among 110 companies in the industry, while the industry leader, Huadong Medicine, had revenue of 32.664 billion yuan [2] - The net profit for the same period was 127 million yuan, ranking 46th in the industry, with the industry leader, Heng Rui Medicine, reporting a net profit of 5.76 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, the asset-liability ratio of Shengnuo Biotech was 45.95%, higher than the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 56.67%, lower than the industry average of 57.17% [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 9.53% to 10,100, while the average number of circulating A-shares held per household increased by 10.53% to 15,600 [5] Group 5: Future Outlook - Guotai Junan Securities maintains an "overweight" rating, raising the EPS forecast for 2025-2027 to 1.14, 1.51, and 1.88 yuan, with a target price adjustment to 51.3 yuan [5] - The company is expected to benefit from the booming demand for GLP-1 peptide APIs, with H1 2025 raw material drug revenue reaching 189 million yuan, a year-on-year increase of 232.4% [5][6] - Revenue projections for 2025-2027 are 751 million yuan, 990 million yuan, and 1.21 billion yuan, with net profits of 191 million yuan, 273 million yuan, and 349 million yuan respectively [6]